dostarlimab-gxly
FDA Expands Endometrial Cancer Indication for Jemperli With Chemotherapy
The FDA has approved Jemperli, GSK with carboplatin and paclitaxel for adult patients with primary advanced or ...
AUGUST 2, 2024
Jemperli Gets Full Approval for Endometrial Cancer
The FDA approved Jemperli for adult patients with dMMR recurrent or advanced endometrial cancer, that has ...
FEBRUARY 15, 2023
Jemperli Approval Expanded to Treatment of dMMR Solid Tumors
The FDA granted accelerated approval to the programmed cell death receptor-1 agent dostarlimab-gxly (Jemperli, ...
AUGUST 19, 2021
New PD-1 Jemperli Approved to Treat Mismatch Repair–Deficient Endometrial Cancer
The FDA granted accelerated approval to the programmed death receptor-1-blocking antibody dostarlimab-gxly ...
MAY 4, 2021
Load more